Global cell therapy market value was USD 10.23 billion in 2021. This will continue to grow at a CAGR of 13.3% over the 2023-2032 forecast period.

Cell therapy is a technology that replaces damaged or dysfunctional cells with healthy functioning cells. Because stem cells can differentiate into the cells needed to repair damaged cells or tissue, they are the cells most often used in advanced therapies. Regenerative medicine is another area where cell therapy can be used. It involves the creation of multidisciplinary medicines that aim to maintain, improve or restore cell, tissue, or organ function. In cell therapy, many cells, including blood, bone marrow cells, mature and immature cells, adult stem, and embryonic cells, are used. Furthermore, transplanted cells, including induced pluripotent stem cells(iPSCs), embryonic and neural stem cells(NSCs), as well as mesenchymal and mesenchymal cells (MSCs), can be divided into two main groups: autologous and non-autologous.

Request for Sample Copy of Cell therapy Market with Complete TOC and Figures & Graphs@ https://market.us/report/cell-therapy-market/request-sample

Cell therapy Market: Drivers

A rise in cell-based research and funding has resulted from the demand for new, better drugs for conditions like cancer and CVD. The Australian government published the Stem Cell Therapies Mission in November 2019. It is a 10-year strategy that will support stem cell research within Australia. The Medical Research Future Fund would fund the project with USD 102million (AU$150million) to support stem cell research and develop new medicines. Innovate UK (UK’s innovation agency) was awarded USD 269670 (GBP 267,000) in September 2019 to fund the development of gel stabilization technologies. This was in response to Atelerix’s first goal of increasing the shelf life of Rexgenero cell-based therapies that can be stored and transported at room temperature.

Cell therapy Market: Restraints

Despite technological developments and product advancements over the past decade, the industry has been hindered by a shortage of skilled personnel to operate complicated devices like multi-mode readers and flow cytometers. Technology-intensive devices such as spectrophotometers and flow cytometers can produce many data outputs that require skilled analysis and review. According to the National Accrediting Agency for Clinical Laboratory Sciences, there is a worldwide shortage of competent individuals (NAACLS). Over the next decade, Europe and the UK will likely face severe shortages in laboratory capabilities. The UK’s medical laboratories will be the most severely affected.

Any Query?
Enquire Here for Report Customization: https://market.us/report/cell-therapy-market/#inquiry

Cell therapy Market Key Trends:

Market Share is expected to be significant for the Allogeneic Therapies Segment of Cell Therapy

Allogeneic treatments rely on one source of cells to treat many patients. They can cause an immune response in patients and are often combined with immunosuppressive treatments. This is why physicians are increasingly inclined to use allogeneic therapies therapeutically. There is also a growing awareness of the therapeutic potential of cord cells and other tissues in various therapeutic areas. The benefits of allogenic cells are that they produce immune stem cells which kill any remaining cancer cells even after high-dose chemotherapy with cytotoxic drugs. This is called the graft-versus–cancer effect. It is used for cancer relapse prevention and treatment. Over the forecast period, the market will be driven by the abovementioned factors.

The segment is expected to grow due to the increasing number of clinical trials needed to obtain regulatory approval for new medications. The segment has many growth opportunities, such as ALLO-501, Allo-501A, and ALLO-715.

Additionally, Allogene Therapeutics Inc. & SpringWorks Therapeutics Inc. have entered into a clinical collaboration agreement to evaluate and treat ALLO-715 in multiple myeloma patients.

This is due to the increasing number of research studies about allogenic therapy for cancer treatment and its associated benefits. The forecast period will see steady growth.

Recent development:

Immunocore was approved by the Food and Drug Administration (KIMMTRAK) in January 2022 to treat metastatic or unresectable uveal melanoma.

Novadip Biosciences was approved by the Food and Drug Administration in March 2021 for regenerative bone product NVD003 to treat rare bone diseases.

Scope of the Report

Attribute	Details
Market Size in 2021	USD 10.23 billion
Growth Rate	CAGR of 13.3%
Historical Years	2016-2020
Base Year	2021
Quantitative Units	USD In Bn
No. of Pages in Report	200+ Pages
No. of Tables & Figures	150+
Format	PDF/Excel
Direct Order This Report	Available- To Purchase This Premium Report Click Here

Key Market Players:

Kolon TissueGene Inc.
PHARMICELL Co. Ltd
Anterogen co., ltd.
Osiris Therapeutics Inc.
JCR Pharmaceuticals Co. Ltd.
Vericel Corporation
Castle Creek Biosciences Inc.
Celgene Corporation
Danaher corporation
NuVasive, inc.
smith & nephew
Osiris therapeutics, inc
tameika cell technologies, inc.
Other major Players

By Use-Type

Research-use
Clinical-use

By Therapy Type

Autologous Therapies
Allogenic Therapies

Industry, By Region

Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America [United States, Canada, Mexico]
Middle East & Africa [GCC, North Africa, South Africa]
South America [Brazil, Argentina, Columbia, Chile, Peru]

Key questions:

What is the CAGR for the global cell therapy market in 2019?
Who is the dominant player in the cell therapy market, and why?
What are the driving forces of cell therapy?
What region will be the leader in cell therapy?
What are the top trends in the cell therapy market?
What is the growth % and market value of emerging countries?
Which region holds the largest share of Cell Therapy Market?

More Related Reports from Our Market.us Site:

The global cell therapy monitoring kits market is projected to reach a valuation of USD 4.29 Bn by 2032 at a CAGR of 5.0%, from USD 2.63 Bn in 2022.

In 2021, the global cell culture market accounted for USD 38.58 Billion. It is excepted to register a CAGR of 13% between 2023 to 2032.

The global market for 3D cell culture was worth USD 1.65 Billion in 2021. This market is expected to grow at a 9.8% CAGR.

The Automated Cell Culture Market is projected to reach a valuation of USD 526.22 Mn by 2032 at a CAGR of 7.9%, from USD 228 Mn in 2021.

The global Single-Cell Multiomics Маrkеt is projected to reach USD 18.36 Bn by 2031 at a CAGR of 21.40%, from USD 2.64 Bn in 2021.

Cell Culture Media Market is expected to grow at a CAGR of roughly 7.8% over the next ten years, and will reach USD 1.59 Bn in 2028, from USD 0.7533 Bn in 2018

The global mesotherapy injector gun market is projected to be USD 206.8 in 2020 to reach USD

328.7 Mn by 2030 at a CAGR of 4.8%.

About Market.us

Market.US (Powered by Prudour Private Limited) specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicated market research report providing firm.

Contact Details:

Global Business Development Team – Market.us

Address: 420 Lexington Avenue, Suite 300 New York City, NY 10170, United States

Phone: +1 718 618 4351 (International), Phone: +91 78878 22626 (Asia)

Email: [email protected]

WHAT TO TAKE AWAY FROM THIS ARTICLE:

Despite technological developments and product advancements over the past decade, the industry has been hindered by a shortage of skilled personnel to operate complicated devices like multi-mode readers and flow cytometers.
Because stem cells can differentiate into the cells needed to repair damaged cells or tissue, they are the cells most often used in advanced therapies.
There is also a growing awareness of the therapeutic potential of cord cells and other tissues in various therapeutic areas.